METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Clinical trials for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Targeted radiation attack on advanced prostate cancer begins human testing
Disease control Not yet recruitingThis study is testing a new two-part treatment for men with advanced prostate cancer that has spread and is no longer responding to standard hormone therapy. First, a small radioactive tracer finds the cancer cells. Then, a stronger radioactive drug delivers a targeted dose of ra…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1, PHASE2 • Sponsor: Chengdu StarRay Therapeutics Co., Ltd • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
Alzheimer's drug tested as new hope for tough prostate cancer
Disease control Not yet recruitingThis study is testing if a drug called memantine hydrochloride, commonly used for Alzheimer's disease, can help control advanced prostate cancer that has spread and stopped responding to standard hormone therapies. It will involve about 15 men who have already tried one or two ot…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE2 • Sponsor: Bin Xu • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
New Two-Pronged attack tested for Tough-to-Treat prostate cancer
Disease control Not yet recruitingThis early-stage trial is testing the safety of a new two-drug combination for men with advanced prostate cancer that has spread and is no longer responding to standard hormone treatments. The treatment pairs a radioactive drug that targets cancer cells with an immunotherapy drug…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1 • Sponsor: Cellbion Co., Ltd. • Aim: Disease control
Last updated Mar 11, 2026 14:54 UTC